Shares of Staar Surgical Co. (NASDAQ:STAA) have received an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company.
Analysts have set a twelve-month consensus price objective of $6.00 for the company, according to Zacks. Zacks has also given Staar Surgical an industry rank of 82 out of 265 based on the ratings given to related companies.
Several equities research analysts recently commented on STAA shares. Zacks Investment Research raised shares of Staar Surgical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 13th. William Blair reaffirmed a “market perform” rating on shares of Staar Surgical in a research report on Thursday, August 4th.
In other Staar Surgical news, major shareholder Broadwood Partners Lp purchased 14,144 shares of the stock in a transaction on Wednesday, June 29th. The shares were purchased at an average cost of $5.24 per share, for a total transaction of $74,114.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.60% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the stock. American International Group Inc. raised its stake in shares of Staar Surgical by 1.3% in the second quarter. American International Group Inc. now owns 23,042 shares of the company’s stock valued at $127,000 after buying an additional 287 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Staar Surgical by 2.0% in the second quarter. California State Teachers Retirement System now owns 83,932 shares of the company’s stock valued at $462,000 after buying an additional 1,684 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Staar Surgical by 5.4% in the second quarter. Alliancebernstein L.P. now owns 54,300 shares of the company’s stock valued at $299,000 after buying an additional 2,800 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Staar Surgical by 1.6% in the first quarter. Geode Capital Management LLC now owns 193,933 shares of the company’s stock valued at $1,433,000 after buying an additional 3,015 shares during the last quarter. Finally, SECOR Capital Advisors LP raised its stake in shares of Staar Surgical by 17.0% in the second quarter. SECOR Capital Advisors LP now owns 25,866 shares of the company’s stock valued at $142,000 after buying an additional 3,757 shares during the last quarter. Hedge funds and other institutional investors own 74.19% of the company’s stock.
Staar Surgical (NASDAQ:STAA) traded down 1.89% during midday trading on Friday, reaching $9.32. 11,702 shares of the company’s stock were exchanged. The company’s market cap is $376.82 million. Staar Surgical has a 52 week low of $4.98 and a 52 week high of $9.78. The firm has a 50-day moving average price of $8.91 and a 200 day moving average price of $7.16.
Staar Surgical (NASDAQ:STAA) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $21 million for the quarter, compared to analysts’ expectations of $19.88 million. Staar Surgical had a negative net margin of 16.00% and a negative return on equity of 7.12%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. Analysts anticipate that Staar Surgical will post ($0.30) EPS for the current year.
Staar Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses (IOLs) used in cataract surgery and implantable collamer lenses (ICLs) used in refractive surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Staar Surgical Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Staar Surgical Co. and related companies with MarketBeat.com's FREE daily email newsletter.